Sanofi (NASDAQ: SNY) Stock Competitors & Peer Comparison
See SNY's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SNY and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SNY | $47.04 | +0.28% | 113.7B | 10.24 | $4.59 | +5.18% |
| LLY | $1,354.00 | -0.79% | 1.3T | 43.57 | $31.49 | +0.49% |
| JNJ | $276.22 | +1.43% | 664.8B | 25.74 | $10.73 | +1.92% |
| ABBV | $291.31 | +1.07% | 514.9B | 28.59 | $10.19 | +2.39% |
| MRK | $146.73 | -0.14% | 362B | 45.70 | $3.21 | +2.32% |
| NVS | $162.55 | +0.38% | 307B | 18.71 | $8.69 | +2.93% |
| AZN | $186.43 | -0.22% | 289.1B | 20.13 | $9.26 | +1.74% |
| AMGN | $460.42 | +0.03% | 248.8B | 20.57 | $22.37 | +2.16% |
| GILD | $166.89 | -0.41% | 206.9B | -427.74 | -$0.39 | +1.94% |
| NVO | $40.31 | +0.02% | 177.7B | 10.03 | $4.02 | +4.46% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
SNY vs LLY Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, LLY has a market cap of 1.3T. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while LLY trades at $1,354.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas LLY's P/E ratio is 43.57. In terms of profitability, SNY's ROE is +0.06%, compared to LLY's ROE of +0.84%. Regarding short-term risk, SNY is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for SNY.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
SNY vs JNJ Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, JNJ has a market cap of 664.8B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while JNJ trades at $276.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas JNJ's P/E ratio is 25.74. In terms of profitability, SNY's ROE is +0.06%, compared to JNJ's ROE of +0.20%. Regarding short-term risk, SNY is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for SNY.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
SNY vs ABBV Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, ABBV has a market cap of 514.9B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while ABBV trades at $291.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas ABBV's P/E ratio is 28.59. In terms of profitability, SNY's ROE is +0.06%, compared to ABBV's ROE of -2.03%. Regarding short-term risk, SNY is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for SNY.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
SNY vs MRK Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, MRK has a market cap of 362B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while MRK trades at $146.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas MRK's P/E ratio is 45.70. In terms of profitability, SNY's ROE is +0.06%, compared to MRK's ROE of +0.05%. Regarding short-term risk, SNY is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for SNY.Check MRK's competition here
Novartis AG (NYSE: NVS)
SNY vs NVS Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, NVS has a market cap of 307B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while NVS trades at $162.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas NVS's P/E ratio is 18.71. In terms of profitability, SNY's ROE is +0.06%, compared to NVS's ROE of +0.25%. Regarding short-term risk, SNY is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for SNY.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
SNY vs AZN Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, AZN has a market cap of 289.1B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while AZN trades at $186.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas AZN's P/E ratio is 20.13. In terms of profitability, SNY's ROE is +0.06%, compared to AZN's ROE of +0.22%. Regarding short-term risk, SNY is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for SNY.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
SNY vs AMGN Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, AMGN has a market cap of 248.8B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while AMGN trades at $460.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas AMGN's P/E ratio is 20.57. In terms of profitability, SNY's ROE is +0.06%, compared to AMGN's ROE of +0.86%. Regarding short-term risk, SNY is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for SNY.Check AMGN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
SNY vs GILD Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, GILD has a market cap of 206.9B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while GILD trades at $166.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas GILD's P/E ratio is -427.74. In terms of profitability, SNY's ROE is +0.06%, compared to GILD's ROE of -0.22%. Regarding short-term risk, SNY is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for SNY.Check GILD's competition here
Novo Nordisk A/S (NYSE: NVO)
SNY vs NVO Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, NVO has a market cap of 177.7B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while NVO trades at $40.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas NVO's P/E ratio is 10.03. In terms of profitability, SNY's ROE is +0.06%, compared to NVO's ROE of +0.54%. Regarding short-term risk, SNY is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for SNY.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
SNY vs PFE Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, PFE has a market cap of 167.5B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while PFE trades at $29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas PFE's P/E ratio is 9.63. In terms of profitability, SNY's ROE is +0.06%, compared to PFE's ROE of +0.05%. Regarding short-term risk, SNY is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for SNY.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
SNY vs BMY Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, BMY has a market cap of 127.1B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while BMY trades at $62.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas BMY's P/E ratio is 10.48. In terms of profitability, SNY's ROE is +0.06%, compared to BMY's ROE of +0.44%. Regarding short-term risk, SNY is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for SNY.Check BMY's competition here
GSK plc (NYSE: GSK)
SNY vs GSK Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, GSK has a market cap of 101.8B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while GSK trades at $50.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas GSK's P/E ratio is 10.87. In terms of profitability, SNY's ROE is +0.06%, compared to GSK's ROE of +0.23%. Regarding short-term risk, SNY is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for SNY.Check GSK's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
SNY vs CELG-RI Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, CELG-RI has a market cap of 94.8B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while CELG-RI trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, SNY's ROE is +0.06%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, SNY is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for SNY.Check CELG-RI's competition here
Biogen Inc. (NASDAQ: BIIB)
SNY vs BIIB Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, BIIB has a market cap of 36.7B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while BIIB trades at $248.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas BIIB's P/E ratio is 15.69. In terms of profitability, SNY's ROE is +0.06%, compared to BIIB's ROE of +0.02%. Regarding short-term risk, SNY is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for SNY.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
SNY vs HZNP Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas HZNP's P/E ratio is 61.86. In terms of profitability, SNY's ROE is +0.06%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, SNY is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for SNY.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
SNY vs GRFS Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, GRFS has a market cap of 7.1B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while GRFS trades at $8.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas GRFS's P/E ratio is 9.69. In terms of profitability, SNY's ROE is +0.06%, compared to GRFS's ROE of +0.09%. Regarding short-term risk, SNY is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for SNY.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
SNY vs OGN Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while OGN trades at $13.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas OGN's P/E ratio is 4.13. In terms of profitability, SNY's ROE is +0.06%, compared to OGN's ROE of +0.22%. Regarding short-term risk, SNY is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for SNY.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
SNY vs AMRN Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, AMRN has a market cap of 241.1M. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while AMRN trades at $11.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas AMRN's P/E ratio is -116.55. In terms of profitability, SNY's ROE is +0.06%, compared to AMRN's ROE of -0.04%. Regarding short-term risk, SNY is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for SNY.Check AMRN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
SNY vs MIRA Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, MIRA has a market cap of 23.3M. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while MIRA trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas MIRA's P/E ratio is -0.38. In terms of profitability, SNY's ROE is +0.06%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, SNY is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for SNY.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLX)
SNY vs SCLX Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, SCLX has a market cap of 11.7M. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while SCLX trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas SCLX's P/E ratio is -0.04. In terms of profitability, SNY's ROE is +0.06%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, SNY is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for SNY.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
SNY vs SCLXW Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, SCLXW has a market cap of 7.6M. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while SCLXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas SCLXW's P/E ratio is N/A. In terms of profitability, SNY's ROE is +0.06%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, SNY is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for SNY.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
SNY vs BDSIW Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, SNY's ROE is +0.06%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, SNY is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for SNY.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
SNY vs CRXT Comparison November 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 113.7B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, SNY is priced at $47.04 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 10.24, whereas CRXT's P/E ratio is -0.02. In terms of profitability, SNY's ROE is +0.06%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, SNY is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for SNY.Check CRXT's competition here